Substance / Medication

Fluoxymesterone

Overview

Active Ingredient
fluoxymesterone
RxNorm CUI
4494

Indications

In the male —HALOTESTIN Tablets are indicated for In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis

Labeler: Pharmacia and Upjohn CompanyUpdated: 2006-02-06T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Known hypersensitivity to the drug Males with carcinoma of the breast Males with known or suspected carcinoma of the prostate gland Women known or suspected to be pregnant Patients with serious cardiac, hepatic or renal disease

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

52 trials linked to this intervention

52
Total Trials
6
Recruiting
16
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Fluoxymesterone-induced gynaecomastia in a patient with childhood aplastic anaemia.
Lo Tom Edward Ngo, Andal Zillien C, Lantion-Ang Frances Lina · BMJ Case Rep · 2015
PMID: 25948845Case ReportFull text (PMC)
The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation.
Fürstenberger Cornelia, Vuorinen Anna, Da Cunha Thierry et al. · Toxicol Sci · 2012
PMID: 22273746Preclinical
Characterization and quantification of fluoxymesterone metabolite in horse urine by gas chromatography/mass spectrometry.
Yamada Masayuki, Aramaki Sugako, Hosoe Tomoo et al. · Anal Sci · 2008
PMID: 18614835Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fluoxymesterone (substance)
SNOMED CT
126125005
UMLS CUI
C0016366
RxNorm CUI
4494
Labeler
Pharmacia and Upjohn Company

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
52
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.